3 Biotech Stocks With Massive Upside Potential In Q4 2020

The biotechnology industry is one of the most important industries in the world.

That’s especially true today as everyone is trying to develop a vaccine to stop the spread of COVID-19.

But just because coronavirus is getting all the headlines, that doesn’t mean other diseases have stopped existing and spreading altogether.

In fact, I feel like they’re being more overlooked now than ever.

That’s why I think investors should be scooping up these top three biotech stocks before the rest of Wall Street catches on…

The #3 Biotech Stock of 2020

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a biopharmaceutical company that develops clinical-stage small-molecule therapies for central nervous system disorders.

[finviz ticker=VNDA]

On August 31, Vanda reported that the Phase III study of its drug, Tradipitant, was progressing and is expected to be completed in the first half of 2021.

Tradipitant has potential applications in the treatment of gastroparesis.

This a disease related to the stomach that an estimated 6 million people suffer from in the U.S. alone.

It’s also a possible means of accelerating clinical improvement in patients with COVID-19 pneumonia.

Investors would be wise to scoop up VNDA shares now before the FDA approves the Tradipitant next year and the stock pops.

The #2 Biotech Stock of 2020

Trillium Therapeutics Inc. (NASDAQ: TRIL) is a Canadian biotech firm that specializes in clinical-stage immuno-oncology treatments.

[finviz ticker=TRIL]

It has preclinical programs and therapies that focus on treating cancer.

Trillium’s lead program is called “TTI-621” which is designed to act as a soluble decoy receptor, preventing CD47 (a high affinity receptor that plays a role in vascular development and angiogenesis) from delivering its inhibitory signal.

TRIL has a proprietary medicinal chemistry platform that uses fluorine chemistry. This permits the creation of new chemical entities with pharmacological properties.

The stock is up big time in 2020 – from $1.03 per share on Dec. 31, 2019 to $12.45 today.

That’s a 1,108% return for investors so far in 2020. And 2021 could deliver something similar.

The #1 Biotech Stock of 2020

Jeff Brown is arguably America’s #1 most accurate technology investor.

In 2015, he singled out Bitcoin before it shot up almost 100x…

He also recommended the #1 tech investments of 2016, 2018, and 2019…

And—this year—he’s already picked two of the three top-performing stocks!

Recently, Mr. Brown sat down with Chris Hurt to discuss the state of the stock market…

And discuss his new #1 pick.

As you’ll see, it’s in an industry that billionaires like

Jeff Bezos and Warren Buffett are flocking to…

(In fact, Buffett recently dumped $800 million of Apple stock to invest in this!)

It’s also set to grow an astonishing 5,900%.

If you have any interest in tech stocks, you can’t miss this special interview. And the new report Jeff Brown put together.

You can click here for the special interview.

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works